摘要
目的:分析以端粒酶为靶点的中药人参健脾丸治疗原发性肝癌的情况。方法:选58例均属中晚期肝癌患者,经PCR-TRAP法检测,均具有端粒酶活性,治疗组38例行TACE法治疗同时配合人参健脾丸口服;对照组单纯采用TACE法。结果:人参健脾丸能有效降低肝癌患者体内TLMA的活性;减轻化学介入治疗对消化道的毒副作用、对骨髓的抑制;改善患者的生活质量;提高T淋巴细胞的活性而起到抗肿瘤的效应。结论:人参健脾丸作为端粒酶抑制剂在原发性肝癌的辅助治疗中具有重要的意义。
Objective：To analyze 38 cases of enforce spleen pill of ginseng treatment HCC by telomerase for target. Methods： To take out 58 cases patience in the middle and last term, there are all active of telomerase by PCR - TRAP. There are 38 patients in group of treatment by TACE, at the same time to take orally enforce spleen pill of ginseng. The group of contrast is only taken TACE. Results： Enforce spleen pill is good for the patients with liver cancer. Conclusions： Enforce spleen pill of ginseng take play a role in treatment of secondly HCC as inhibition of telomerase.
出处
《中国民康医学》
2008年第7期627-629,共3页
Medical Journal of Chinese People’s Health
关键词
原发性肝癌
端粒酶活性
人参健脾丸
HCC
Active of telomerase
Enforce spleen pill of ginseng
